Where commercial activity sits
Chiefly in monitoring: handheld videomicroscopy systems, near-infrared spectroscopy, and the analysis software that makes them clinically usable. The commercial case rests on whether microcirculation-guided management changes decisions and outcomes, which is not yet established.
Biomarker assays for endothelial and glycocalyx damage are a second area, positioned for risk stratification and trial enrichment.
The sober context
Sepsis therapeutics has one of the least successful trial records in medicine. Many agents with strong preclinical rationale failed in phase III, attributed to heterogeneity of the syndrome, late intervention, and endpoints insensitive to the mechanism targeted.
That history is the relevant base rate for claims about new sepsis interventions, including microcirculation-directed ones. Enthusiasm from mechanism is exactly what the record cautions against.
What would change the picture
Enrichment: identifying the subgroup with the targeted abnormality rather than treating undifferentiated sepsis. This is the main lesson drawn from the failures and underlies current interest in sepsis sub-phenotypes.
Earlier intervention, and endpoints sensitive to the mechanism rather than all-cause mortality alone in a heterogeneous population.
For authors and readers
Device evidence requires the same scrutiny as drug evidence, and often receives less. A monitor is validated by showing that its output changes management and that the change benefits patients — not by showing it correlates with another measure.
Report device studies to the relevant standards, declare manufacturer involvement in design and analysis, and distinguish regulatory clearance from evidence of clinical benefit.
In short
What to take from this.
- The sepsis trial record is the base rate for mechanism-driven optimism.
- A monitor is validated by changed management and improved outcome, not correlation.
- Distinguish regulatory clearance from evidence of benefit.
Sources
- Literature on failed sepsis trials and sub-phenotype enrichment
- Device evaluation and reporting standards
This page reflects established understanding as at mid-2026 and is not a current-awareness service. Clinical and regulatory positions change; verify anything decision-relevant against a current source.
Related